首页> 美国卫生研究院文献>Journal of the International AIDS Society >Causes of virological failure in a population of 1895 HIV-infected patients: the experience of an infectious diseases service in Lisbon Portugal
【2h】

Causes of virological failure in a population of 1895 HIV-infected patients: the experience of an infectious diseases service in Lisbon Portugal

机译:1895年感染HIV的患者中病毒学失败的原因:葡萄牙里斯本的传染病服务经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite the increasing optimization of combined antiretroviral therapy (cART) regimens in the last decades, a significant percentage of patients still do not achieve viral replication control. We present a retrospective analysis focusing on human immunodeficiency virus (HIV)-infected population on cART, followed at our ambulatory care clinic between 1st January and 31st December 2011, in order to identify the causes of virological failure. From the 1895 patients in our population we included 1854 in the study. Ten percent (187) of the included patients had detectable HIV RNA (≥40 cp/mL) at the time of last laboratory evaluation: 70,1% were males, mean age was 46 years and 72,7% were Portuguese. Patients with detectable HIV RNA were divided into group A (HIV RNA <200 cp/mL) - 78 (41,7%) patients and group B (HIV RNA ≥200 cp/mL) 109 (58,3%) patients. The comparison of both groups revealed an higher mean count of TCD4+ (568 vs 334 cells/mm3; p<0,001) in group A, although similar mean TCD4+ count at time of cART initiation (276 vs 262 cells/mm3; p=0,412). Group A patients experienced longer exposure to cART (10 vs 8 years; p<0,05) and have undergone, on average, 3 previous regimens (p<0,05). With regard to cARV current regimen: 32,1% patients in group A and 30,3% in group B were prescribed non-nucleoside reverse transcriptase inhibitors based regimes and 51,3% patients in Group A and 59,6% in group B were under cARV based on Protease inhibitors. The identified causes of virologic failure for patients with detectable HIV RNA were: poor adherence (54%); unsuccessful retention in care (14,4%); sporadic detectable HIV RNA (40≤viral load<200), “blips” (14,4%); mutations of resistance to ARVs (13,4%); intolerance to the current regimen (2,1%) and pharmacokinetics drug interactions (1,6%). The estimated rate of virological failure was 10,1% in this population. Insufficient adherence and unsuccessful retention in care were identified in 68,4% of treatment failed patients as main causes of virological failure. Failure of therapy due to intolerance or adverse effects was reported in 2,1% of cases, reflecting a better safety profile and tolerability of recent prescribed regimens. Early identification of causes of virologic failure, timely adjustment of therapeutic regimens, and the adoption of measures to promote adherence and retention in care are key factors for successful treatment of HIV-infected patients.
机译:尽管最近几十年来联合抗逆转录病毒疗法(cART)方案的优化不断提高,但仍有相当一部分患者仍未实现病毒复制控制。我们进行了一项回顾性分析,重点是在cART上针对人类免疫缺陷病毒(HIV)感染的人群,然后在2011年1月1日至12月31日之间在我们的门诊诊所进行调查,以确定病毒学失败的原因。从我们人口中的1895位患者中,我们将1854年纳入研究。在上次实验室评估时,纳入的患者中有10%(187)具有可检测到的HIV RNA(≥40cp / mL):男性为70.1%,平均年龄为46岁,葡萄牙为72.7%。可检测到HIV RNA的患者分为A组(HIV RNA <200 cp / mL)-78名(41.7%)患者和B组(HIV RNA≥200cp / mL)109名(58.3%)患者。两组的比较显示,A组的TCD4 +平均计数较高(568比334细胞/mm3;p<0.001),尽管在cART启动时平均T​​CD4 +计数相似(276比262)个/ mm 3 ; p = 0,412)。 A组患者经历了更长的cART暴露时间(10年比8年; p <0.05),平均之前接受过3种治疗方案(p <0.05)。关于cARV现行方案:A组中有32.1%的患者和B组中有30.3%的患者采用了基于非核苷逆转录酶抑制剂的治疗方案,A组中有51.3%的患者以及B组中有59.6%的患者处于基于蛋白酶抑制剂的cARV中。对于可检测到的HIV RNA患者,确定的病毒学失败原因包括:依从性差(54%);护理保留不成功(14.4%);零星可检测的HIV RNA(40≤病毒载量<200),“斑点”(14.4%);对ARV的耐药性突变(13.4%);对当前方案的不耐受性(2.1%)和药代动力学药物相互作用(1.6%)。该人群的病毒学失败率估计为10,1%。在治疗失败的患者中,有68.4%的依从性不足和对护理的保留不足是病毒学失败的主要原因。据报道,有2.1%的病例由于不耐受或不良反应而导致治疗失败,这反映出近期处方方案的安全性和耐受性更高。尽早发现病毒学衰竭的原因,及时调整治疗方案以及采取措施以促进依从性和对护理的保留是成功治疗HIV感染患者的关键因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号